Seaview Securities Appoints Kenneth Kulju as Managing Director

NEW YORK, June 4 /PRNewswire/ -- Seaview Securities LLC, a leading life sciences specialty investment bank, today announced that Kenneth R. Kulju has joined the firm as a Managing Director. During Mr. Kulju's long and distinguished career as a sell side equity research analyst, he has covered both the specialty and major pharmaceutical sectors. Most recently, Mr. Kulju headed the U.S. Healthcare Equity Capital Markets group for Credit Suisse in New York, with responsibility for financing both life science and services sector companies.

"Ken's insight and judgment have long been highly valued by life science company management teams and fund managers alike," said Joseph P. Dougherty, Ph.D., Managing Director at Seaview. "We are delighted that Ken will bring his highly complementary expertise to expand our life sciences banking practice at Seaview."

Mr. Kulju's background includes more than 22 years of experience as an equity research analyst. He was ranked as the #1 specialty pharmaceuticals analyst in the Institutional Investor surveys in 1999 and 2000, and Fortune All-Star Analyst rankings in 2000 and 2001.

During his Wall Street career, Mr. Kulju's coverage universe broadly addressed major and specialty pharmaceuticals during tenures at Credit Suisse from 2001 to 2008, where he held the position of Team Leader for the Credit Suisse Healthcare equity research group from 2003-2006; Donaldson Lufkin & Jenrette (now Credit Suisse) from 1998 to 2000; UBS from 1993 to 1997 and Rothschild from 1988 to 1992.

Within capital markets and research, Mr. Kulju has worked on more than 35 financing transactions raising aggregated capital in excess of $8.0 billion.

Mr. Kulju received his MBA from Drexel University in Finance, and a BS degree from Pennsylvania State University in Business Administration.

About Seaview Securities LLC

Seaview Securities LLC is a specialty investment bank assisting life sciences companies with private placements, public offerings, M&A and strategic advice.

Seaview seeks to bridge the gap between companies and investors by delivering better advice to companies and more carefully vetted deals to investors.

Seaview's approach is unique because we combine deep expertise in investment banking with the technical and market feedback that was traditionally the province of equity research -- a combination of skills essential to meet the needs of our investment banking clients in the technically complex field of life sciences. For additional information, please visit

SOURCE Seaview Securities LLC